News

  • EA Pharma strengthens its international presence with the acquisition of the Spanish Group DRASANVI, its fourth build-up with Motion

    EA Pharma strengthens its international presence with the acquisition of the Spanish Group DRASANVI, its fourth build-up with Motion

    Read more
  • Motion Equity Partners enters into exclusive negotiations for the acquisition of Résilians

    Motion Equity Partners enters into exclusive negotiations for the acquisition of Résilians

    Read more
  • Motion Equity Partners announces the signing of an exclusivity agreement with Latour Capital for the disposal of its shareholding in Omni-Pac Group

    Motion Equity Partners announces the signing of an exclusivity agreement with Latour Capital for the disposal of its shareholding in Omni-Pac Group

    Read more
  • Motion Equity Partners continues its development and promotes a new Partner

    Motion Equity Partners continues its development and promotes a new Partner

    Read more
  • Motion Equity Partners has acquired a stake in Educastream alongside its Managament team to accelerate growth

    Motion Equity Partners has acquired a stake in Educastream alongside its Managament team to accelerate growth

    Read more
  • Motion Equity Partners announces the signing of an exclusivity agreement with Eurazeo PME for the disposal of its shareholding in Altaïr Group.

    Motion Equity Partners announces the signing of an exclusivity agreement with Eurazeo PME for the disposal of its shareholding in Altaïr Group.

    Read more
  • Motion Equity Partners invests in Olmix Group alongside its Founder

    Motion Equity Partners invests in Olmix Group alongside its Founder

    Read more
  • CDL Omni-Pac becomes Omni-Pac Group to reflect its significantly strengthened pan-European presence following the acquisition of MFP in the United-Kingdom early 2020

    CDL Omni-Pac becomes Omni-Pac Group to reflect its significantly strengthened pan-European presence following the acquisition of MFP in the United-Kingdom early 2020

    Read more
  • Equilibre Attitude (EA Pharma) strengthens its expertise in Oligotherapy with the acquisition of Labcatal, its third build-up under Motion ownership

    Equilibre Attitude (EA Pharma) strengthens its expertise in Oligotherapy with the acquisition of Labcatal, its third build-up under Motion ownership

    Read more